Clinical Trial Update: Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in people with chronic hepatitis B who are HBeAg-negative.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HBeAg-negative Chronic Hepatitis B | Phase 3 | Status: COMPLETED | Results posted: 2017-03-30